» Articles » PMID: 17047030

Activation of Mouse and Human Peroxisome Proliferator-activated Receptors (alpha, Beta/delta, Gamma) by Perfluorooctanoic Acid and Perfluorooctane Sulfonate

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2006 Oct 19
PMID 17047030
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

This study evaluates the potential for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) to activate peroxisome proliferator-activated receptors (PPARs), using a transient transfection cell assay. Cos-1 cells were cultured in Dulbecco's Minimal Essential Medium (DMEM) with fetal bovine serum in 96-well plates and transfected with mouse or human PPARalpha, beta/delta, or gamma reporter plasmids. Transfected cells were exposed to PFOA (0.5-100 microM), PFOS (1-250 microM), positive controls (i.e., known agonists and antagonists), and negative controls (i.e., DMEM, 0.1% water, and 0.1% dimethyl sulfoxide). Following treatment for 24 h, activity was measured using the Luciferase reporter assay. In this assay, PFOA had more transactivity than PFOS with both the mouse and human PPAR isoforms. PFOA significantly increased mouse and human PPARalpha and mouse PPARbeta/delta activity relative to vehicle. PFOS significantly increased activation of mouse PPARalpha and PPARbeta/delta isoforms. No significant activation of mouse or human PPARgamma was observed with PFOA or PFOS. The PPARalpha antagonist, MK-886, significantly suppressed PFOA and PFOS activity of mouse and human PPARalpha. The PPARgamma antagonist, GW9662, significantly suppressed PFOA activity on the human isoform. In conclusion, this study characterized the dose response and differential activation of mouse and human PPARalpha, beta/delta, gamma by PFOA and PFOS. While this model allows opportunities to compare potential activation by perfluoroalkyl acids, it only evaluates the interaction and activation of the PPAR reporter constructs and is not necessarily predictive of a toxicological response in vivo.

Citing Articles

Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.


Perfluorooctanoic acid increases serum cholesterol in a PPARα-dependent manner in female mice.

Nielsen G, Gondim D, Cave M, Heiger-Bernays W, Webster T, Schlezinger J Arch Toxicol. 2025; .

PMID: 40021516 DOI: 10.1007/s00204-025-03984-7.


Specific and potent inhibition of steroid hormone pre-receptor regulator AKR1C2 by perfluorooctanoic acid: Implications for androgen metabolism.

Andress Huacachino A, Chung A, Sharp K, Penning T J Steroid Biochem Mol Biol. 2024; 246():106641.

PMID: 39571823 PMC: 11652220. DOI: 10.1016/j.jsbmb.2024.106641.


Effects of Perfluorinated Alkyl Substances (PFAS) on Amphibian Body and Liver Conditions: Is Lipid Metabolism Being Perturbed throughout Metamorphosis?.

Bushong A, Sepulveda M, Scherer M, Valachovic A, Neill C, Horn S Toxics. 2024; 12(10).

PMID: 39453152 PMC: 11510839. DOI: 10.3390/toxics12100732.


Exposure of Mice to a PFAS Mixture and Outcomes Related to Circulating Lipids, Bile Acid Excretion, and the Intestinal Transporter ASBT.

Roth K, Yang Z, Agarwal M, Birbeck J, Westrick J, Lydic T Environ Health Perspect. 2024; 132(8):87007.

PMID: 39177951 PMC: 11343043. DOI: 10.1289/EHP14339.